Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03836443
Other study ID # D20180507
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 14, 2019
Est. completion date June 22, 2023

Study information

Verified date April 2023
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nonalcoholic fatty liver disease (NAFLD) is mainly considered a nutrition-related disease and life-style/diet interventions showed some promising results. But in spite of this, there are no available markers to efficiently guide interventions. the hypothesize put farth by the investigators is that NAFLD patients develop postprandial abnormalities of plasma lipids upon "western diet" challenge, more severe in steatohepatitis (NASH) than in pure steatosis (NAFL), promoting liver injury. Our study aims to evaluate the presence of toxic lipids (such as free-fatty acids, ceramides, diacylglycerols, sphingolipids) in postprandial state after ingestion of a "western diet" in NAFLD patients. Consecutive patients (group 1: NAFL patients; group 2: NASH patients) with biopsy-proven NAFLD (liver biopsy < 6 months) will be recruited during a period of 12 month. Blood samples will be drawn at fasting, 2hours, 4hours, 6hours and 8hours after ingestion of a "western diet" meal. Plasma lipid profiles using lipidomics, circulating markers of liver injury and inflammation will be analyzed. the investigators will also assess the hepatotoxicity of plasma from NAFL or NASH patients in-vitro.


Description:

Factors driving progression from steatosis (NAFL) to steatohepatitis (NASH) in patients with non-alcoholic fatty liver disease (NAFLD) remain largely unknown. Considerable data now indicate that steatosis per se is not a hepatotoxic event and may represent in fact a protective mechanism against free fatty acid (FFA)-induced toxicity. the investigators previously showed that Kupffer cells from NASH mice accumulate more toxic lipids (ceramides, diacylglycerols, sphingolipids) enhancing their proinflammatory polarization. Therefore, "quality" of accumulating lipids rather than "quantity" may play a central role in NAFLD progression. This is a pilot comparative study aiming to evaluate the presence of toxic lipids (such as free-fatty acids, ceramides, diacylglycerols, sphingolipids) in postprandial state after ingestion of a "western diet" in NAFL and NASH patients. The secondary outcomes were: to evaluate the relationship between postprandial circulating lipids and markers of liver injury and proinflammatory cytokines; to evaluate hepatotoxicity of postprandial lipids in vitro. A total of 24 consecutive patients (group 1: 12 NAFL patients; group 2: 12 NASH patients) with biopsy-proven NAFLD (liver biopsy < 6 months) will be recruited. A dietary evaluation covering the 2 previous weeks will be performed. Detailed anthropometric data will be collected (body mass index, waist and hip circumferences, abdominal height, cutaneous skinfolds) and serum metabolic parameters (standard lipid profile, lipoprotein levels, fasting plasma glucose, insulin levels, C-peptide levels, hemoglobin A1c) will be evaluated. After a 12hours overnight fast, patients will undergo an oral "western diet" test consisting in the ingestion of a high saturated fat, high refined sugar, high fructose-meal called "western diet" (800 kcal/meal). Blood samples will be drawn at fasting and then 2, 4, 6 and 8hours after ingestion of the standard meal. Each time plasma and serum samples will be stored at -80°C for subsequent analysis. Lipidomics will be used to quantify each plasma lipid class (neutral lipids, phospholipids and fatty acid methyl esters). Serum levels of cytokines will be assessed using multiple assay technology. Markers of liver injury will be assessed (aminotransferases, Keratin 18 fragments, microRNA-122) in the serum. Hepatocytes will be cultured with plasma from NAFL or NASH patients, and incubated overnight. In vitro hepatotoxicity will be evaluated using TUNEL assay, MTT assay and LDH release assay. the investigators anticipate that inflammation together with hepatocyte death will occur in NAFLD patients who develop specific postprandial plasma lipid changes with an increase in toxic lipid levels. Such patients may develop more severe liver lesions (inflammation, fibrosis/cirrhosis) and benefit of interventions. Identification of a toxic plasma lipid profile may help choosing the adequate diet in order to prevent deleterious lipid formation. Identification of a toxic postprandial plasma lipid signature specific to hepatotoxicity may also serve to develop a discrimination index to be further validated in clinical practice.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 22, 2023
Est. primary completion date June 22, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - histological proven NAFLD (liver biopsy <6 months); hospitalised or outpatients followed up for NAFLD; patients giving their consent for the study; patients covered by health insurance. Exclusion Criteria: - history of excessive alcohol consumption (>20 g/day for males and >10 g/day for females) or other cause of liver injury (viral hepatitis, autoimmune hepatitis, Wilson's disease, hemochromatosis, drug-induced hepatitis, or others); cirrhosis; ongoing hypolipemiant treatment; diabetes; Chronic diarrhea; severe associated disease;Taking antibiotics or probiotics in the last 3 months; Chronic inflammatory bowel disease; Weight =70Kg and hemoglobin level =7g/dl; Allergy to or refusal of any of the elements of the meal provided.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
western diet" meal
A "western diet" meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast.

Locations

Country Name City State
France Kremlin Bicetre hospital Le Kremlin Bicetre

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postprandial changes of plasma lipid fractions measured by lipidomic analysis and expressed as nmolof lipid/ml Lipidomic analysis of plasma lipid fractions expressed in ?m/ml after 12 hours of fasting and in the postprandial period (2h, 4h, 6h, 8h). Plasma samples will be collected at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal to assess postprandial lipid fraction changes
Secondary Circulating markers of liver injury (AST, ALT, cytokeratin 18 fragments, microRNA-122) and serum cytokines (TNF-a, IL-6, IL-1ß, IL-8). Circulating markers of liver injury (AST, ALT, cytokeratin 18 fragments, microRNA-122) and serum cytokines (TNF-a, IL-6, IL-1ß, IL-8) will be measured after 12 hours of fasting and in the postprandial period (2h, 4h, 6h, 8h) in patients with NAFLD After a 12hours overnight fast and then at 2, 4, 6 and 8hours after ingestion of the "western diet" meal.
Secondary Cytotoxic effect of postprandial plasma on hepatocytes in-vitro Hepatocytes will be cultured with postprandial plasma from NAFL or NASH patients, and incubated overnight. In-vitro hepatotoxicity will be evaluated using TUNEL assay, MTT assay and LDH release assay. Plasma samples at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal.
Secondary The effect of supernatants from hepatocyte cultures exposed to patient plasma on human macrophages in vitro Human macrophage will be cultured in vitro with supernatants from hepatocyte cultures exposed to patient plasma Plasma samples at 2hours, 4hours, 6hours and 8hours after ingestion of the "western diet" meal.
Secondary Bacterial microbiome profiles Bacterial microbiome profiles will be measured by the pyrosequencing technique of 16S RNA The day before or the morning before ingestion of the "western diet" meal.
See also
  Status Clinical Trial Phase
Terminated NCT02244944 - Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD Phase 2
Recruiting NCT01544751 - Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin N/A
Recruiting NCT03572465 - Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Enrolling by invitation NCT04059029 - Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
Terminated NCT01930123 - Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease Phase 2
Recruiting NCT01705522 - Multimodal Approach in IBD Patients
Recruiting NCT03525769 - Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes
Completed NCT01265498 - The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) Phase 2
Completed NCT01529268 - Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children Phase 2/Phase 3
Completed NCT02217345 - Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease Phase 2
Completed NCT03486899 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis Phase 2
Completed NCT02781584 - Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) Phase 2
Completed NCT03486912 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Phase 2
Completed NCT02196831 - Tesamorelin Effects on Liver Fat and Histology in HIV N/A
Withdrawn NCT03451279 - A Nonabsorbable Ileal Apical Sodium-Dependent Bile Acid Transporter Inhibitor for Nonalcoholic Steatohepatitis Phase 2
Completed NCT02044523 - Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Completed NCT03042767 - Anti-LPS Antibody Treatment for Pediatric NAFLD Phase 2
Recruiting NCT02213224 - Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Phase 4
Completed NCT03459079 - Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease Phase 2
Not yet recruiting NCT06024408 - A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor Phase 1